MASH曾名为非酒精性脂肪性肝炎（NASH），是代谢功能障碍相关脂肪性肝病（MAFLD）的晚期形式。MASH是导致肝脏相关死亡的主要原因，对全球卫生系统造成日益加重的负担。此外，MASH患者，特别是那些具有更多代谢风险因素（高血压、合并2型糖尿病）的 ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

在当前的医学研究领域，脂肪性肝炎（MASH）作为一种逐渐受到重视的疾病，影响着越来越多的人群，尤其是糖尿病及肥胖症患者。近日，关于司美格鲁肽（Semaglutide）在治疗该病方面的最新研究显示，超过60%的患者在使用该药物后脂肪性肝炎症状明显改善，这无疑为广大患者带来了新的希望。那么，这一研究结果的意义何在？我们该如何理解这一重要发现呢？ 一、脂肪性肝炎的现状与挑战 根据最新的医学统计，脂肪性肝 ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial ...